What is IPAX?
IPAX operates as a specialized contract manufacturer and packager, providing end-to-end solutions for the medical device industry. By offering both low-volume, rapid-turnaround services and high-volume, large-scale production, the company addresses critical bottlenecks in the product development lifecycle. Their facilities, which maintain FDA registration and ISO 13485-2016 certification, underscore a rigorous commitment to regulatory compliance and quality assurance. This operational excellence allows IPAX to serve as a vital partner for innovators looking to reduce capital expenditure while accelerating their time-to-market. The company's business model is built upon the pillars of responsive customer service, precision engineering, and reliable supply chain management, positioning it as a cornerstone for medical device commercialization.
How much funding has IPAX raised?
IPAX has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in IPAX
PPP
Public-Private Partnership
What's next for IPAX?
With this recent capital allocation, IPAX is well-positioned to transition into a phase of aggressive operational expansion. The firm is expected to leverage these resources to upgrade its manufacturing infrastructure, potentially integrating advanced automation to further optimize production efficiency. As the medical device market continues to demand higher standards of quality and faster delivery cycles, IPAX's strategic focus will likely remain on scaling its core competencies while maintaining the agility required to support early-stage ventures. Future growth will be driven by the company's ability to capitalize on the increasing outsourcing trends within the healthcare manufacturing sector, ensuring that it remains a preferred partner for companies navigating the complex regulatory landscape of medical device production.
See full IPAX company page
